Search

Displaying results 3201 - 3210 of 7603 in total
  1. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.

  2. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group o...

  3. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.

  4. Drug

    Domperidone

    go.drugbank.com/drugs/DB01184
    ApprovedInvestigationalVet approved

    A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.

    Categories: Drugs for Functional Gastrointestinal Disorders
  5. Drug

    Elsulfavirine

    go.drugbank.com/drugs/DB14929
    Investigational

    Elsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Uric acid

    go.drugbank.com/drugs/DB08844
    Investigational

    At present (August 2013), there is no approved formulation or indication for uric acid.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma. … AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours.

  8. Drug

    Meprobamate

    go.drugbank.com/drugs/DB00371
    ApprovedIllicit

    It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. … A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation.

  9. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use.

  10. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor. … [A198807] Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19.